Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

MYGN Company Profile and Key Details

NASDAQ : MYGN

Myriad Genetics, Inc.

$10.01
0.1+1.01%
Open: 4:00 PM
62.24
B-ESG ScoreESG Rating

MYGN Stock Price Chart

Stock Price Today

Myriad Genetics, Inc. (MYGN) stock surged +1.01%, trading at $10.01 on NASDAQ, up from the previous close of $9.91. The stock opened at $9.79, fluctuating between $9.68 and $10.30 in the recent session.

Stock Snapshot

9.91
Prev. Close
9.79
Open
914M
Market Cap
91.31M
Number of Shares
9.68
Day Low
10.295
Day High
-7.1
P/E Ratio
95.86%
Free Float in %
-1.41
EPS (TTM)
8.34
Book Value
-1.69
Cash Flow per Share
1.74M
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Mar 21, 20259.7910.309.6810.011.87M
Mar 20, 20259.809.989.739.91565.88K
Mar 19, 20259.8810.069.779.93682.4K
Mar 18, 202510.0010.009.729.90774.79K
Mar 17, 202510.0210.329.8710.12754.46K
Mar 14, 20259.7610.199.7510.07711.4K
Mar 13, 202510.4110.479.709.70853.37K
Mar 12, 202510.9011.4410.3610.411.74M
Mar 11, 20259.6510.309.5010.251.39M
Mar 10, 202510.0610.289.369.611.18M
Mar 07, 202510.5610.5910.0610.18819.6K
Mar 06, 202510.3210.6810.2010.52879.8K
Mar 05, 202510.5110.5710.2110.34968.37K
Mar 04, 202510.2510.6010.1010.421.12M
Mar 03, 202510.8510.9010.3210.391.04M
Feb 28, 202511.0611.2210.4310.731.71M
Feb 27, 202511.6411.6411.0511.061.35M
Feb 26, 202511.8511.8911.2111.561.75M
Feb 25, 202510.3212.289.7611.742.68M
Feb 24, 202514.1614.7313.7413.781.4M

Contact Details

Salt Lake City, UT 84108

United States

Website: https://myriad.comContact: 801 584 3600

About Company

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Company Information

Employees2700
Beta1.79
Sales or Revenue$678.40M
5Y Sales Change%-0.214%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Diagnostics & Research

Frequently Asked Questions

What is the current Myriad Genetics, Inc. (MYGN) stock price?
Myriad Genetics, Inc. (NASDAQ: MYGN) stock price is $10.01 in the last trading session. During the trading session, MYGN stock reached the peak price of $10.30 while $9.68 was the lowest point it dropped to. The percentage change in MYGN stock occurred in the recent session was 1.01% while the dollar amount for the price change in MYGN stock was $0.10.
MYGN's industry and sector of operation?
The NASDAQ listed MYGN is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Myriad Genetics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of MYGN?
Ms. Natalie Munk
Principal Accounting Officer
Mr. Mark S. Verratti
Chief Commercial Officer
Mr. Paul J. Diaz
Chief Executive Officer, Pres & Director
Ms. Nicole Lambert
Chief Operating Officer
Dr. Kevin Richard Haas Ph.D.
Chief Technology Officer
Dr. Clivetty Martinez
Chief Compliance Officer
Mr. Glenn Farrell
Senior Vice President & Chief Marketing Officer
Ms. Pamela Wong
Chief Legal Officer
Mr. R. Bryan Riggsbee
Executive Vice President, Chief Financial Officer & Treasurer
Dr. Dale Muzzey Ph.D.
Chief Scientific Officer
Dr. Kevin Richard Haas
Chief Technology Officer
How MYGN did perform over past 52-week?
MYGN's closing price is 6.94% higher than its 52-week low of $9.36 where as its distance from 52-week high of $29.30 is -65.84%.
How many employees does MYGN have?
Number of MYGN employees currently stands at 2,700.
Link for MYGN official website?
Official Website of MYGN is: https://myriad.com
How do I contact MYGN?
MYGN could be contacted at phone 801 584 3600 and can also be accessed through its website. MYGN operates from 320 Wakara Way, Salt Lake City, UT 84108, United States.
How many shares of MYGN are traded daily?
MYGN stock volume for the day was 1.74M shares. The average number of MYGN shares traded daily for last 3 months was 1.09M.
What is the market cap of MYGN currently?
The market value of MYGN currently stands at $914.00M with its latest stock price at $10.01 and 91.31M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph